JP5094395B2 - Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 - Google Patents

Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 Download PDF

Info

Publication number
JP5094395B2
JP5094395B2 JP2007530543A JP2007530543A JP5094395B2 JP 5094395 B2 JP5094395 B2 JP 5094395B2 JP 2007530543 A JP2007530543 A JP 2007530543A JP 2007530543 A JP2007530543 A JP 2007530543A JP 5094395 B2 JP5094395 B2 JP 5094395B2
Authority
JP
Japan
Prior art keywords
epha4
injury
ephrin
mice
gliosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007530543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008512394A (ja
JP2008512394A5 (enExample
Inventor
ペリー エフ． バートレット
マリー ピー． ガレア
ヨナ ゴールドシュミット
アン エム． ターンレイ
アンドリュー ダブリュ． ボイド
Original Assignee
ザ ユニバーシティー オブ クイーンズランド
ザ ユニヴァーシティー オブ メルボルン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004905148A external-priority patent/AU2004905148A0/en
Application filed by ザ ユニバーシティー オブ クイーンズランド, ザ ユニヴァーシティー オブ メルボルン filed Critical ザ ユニバーシティー オブ クイーンズランド
Publication of JP2008512394A publication Critical patent/JP2008512394A/ja
Publication of JP2008512394A5 publication Critical patent/JP2008512394A5/ja
Application granted granted Critical
Publication of JP5094395B2 publication Critical patent/JP5094395B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2007530543A 2004-09-08 2005-09-08 Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 Expired - Fee Related JP5094395B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2004905148 2004-09-08
AU2004905148A AU2004905148A0 (en) 2004-09-08 A method of treatment and agents useful for same
US64796805P 2005-01-27 2005-01-27
US60/647,968 2005-01-27
PCT/AU2005/001363 WO2006026820A1 (en) 2004-09-08 2005-09-08 Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012030227A Division JP2012136529A (ja) 2004-09-08 2012-02-15 Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置

Publications (3)

Publication Number Publication Date
JP2008512394A JP2008512394A (ja) 2008-04-24
JP2008512394A5 JP2008512394A5 (enExample) 2008-10-09
JP5094395B2 true JP5094395B2 (ja) 2012-12-12

Family

ID=36036018

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007530543A Expired - Fee Related JP5094395B2 (ja) 2004-09-08 2005-09-08 Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置
JP2012030227A Withdrawn JP2012136529A (ja) 2004-09-08 2012-02-15 Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012030227A Withdrawn JP2012136529A (ja) 2004-09-08 2012-02-15 Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置

Country Status (6)

Country Link
US (1) US20080254023A1 (enExample)
EP (1) EP1793854A4 (enExample)
JP (2) JP5094395B2 (enExample)
CA (1) CA2579352A1 (enExample)
NZ (1) NZ553273A (enExample)
WO (1) WO2006026820A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012136529A (ja) * 2004-09-08 2012-07-19 Univ Of Queensland Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP674898A0 (en) 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
MX2009000374A (es) * 2006-07-13 2009-01-27 Novartis Ag Uso de benzamidas substituidas con trifluorometilo en el tratamiento de trastornos neurologicos.
WO2009064006A1 (ja) 2007-11-15 2009-05-22 Eisai R & D Management Co., Ltd. γ-セクレターゼの新規基質EphA7を利用したスクリーニング方法
US7892769B2 (en) * 2007-11-30 2011-02-22 Eisai R&D Management Co., Ltd. Processing of EphA4 polypeptide by γ-secretase activity
EP2260864A1 (en) * 2009-06-10 2010-12-15 University of Melbourne Therapeutic applications
JP6059017B2 (ja) 2010-12-17 2017-01-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼラチナーゼによるＥｐｈＡ４の切断反応を指標としたスクリーニング方法
WO2012147798A1 (ja) 2011-04-25 2012-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 EphA4細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法
WO2016011201A2 (en) * 2014-07-15 2016-01-21 Sanford Burnham Prebys Medical Discovery Institute Epha4 cyclic peptide antagonists for neuroprotection and neural repair
RU2651756C1 (ru) * 2017-05-10 2018-04-23 Федеральное государственное бюджетное образовательное учреждение Высшего Образования Кубанский Государственный Медицинский Университет Министерства Здравоохранения Российской Федерации, КубГМУ Препарат для предотвращения образования глиальных рубцов
WO2021002312A1 (ja) 2019-07-01 2021-01-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ＥｐｈＡ４抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP674898A0 (en) * 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
WO2000030673A1 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Uses for eph receptor antagonists and agonists to treat vascular disorders
EP1553963A4 (en) * 2002-09-24 2006-05-03 Burnham Inst NEW MEANS FOR MODULATING EPH RECEPTOR ACTIVITY
US20040147469A1 (en) * 2002-11-01 2004-07-29 Case Western Reserve University Methods of inhibiting glial scar formation
WO2005056766A2 (en) * 2003-12-04 2005-06-23 Medimmune, Inc. TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES
CA2579352A1 (en) * 2004-09-08 2006-03-16 The University Of Queensland Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012136529A (ja) * 2004-09-08 2012-07-19 Univ Of Queensland Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置

Also Published As

Publication number Publication date
JP2012136529A (ja) 2012-07-19
JP2008512394A (ja) 2008-04-24
EP1793854A1 (en) 2007-06-13
WO2006026820A9 (en) 2007-04-05
NZ553273A (en) 2009-11-27
WO2006026820A1 (en) 2006-03-16
CA2579352A1 (en) 2006-03-16
US20080254023A1 (en) 2008-10-16
EP1793854A4 (en) 2008-01-02

Similar Documents

Publication Publication Date Title
JP2012136529A (ja) Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置
JP5829373B2 (ja) Ｎｏｇｏレセプターアンタゴニスト
EP2994157B1 (en) Tafa4 compounds and uses thereof for treating pain
Kowalski et al. Peripheral loss of EphA4 ameliorates TBI-induced neuroinflammation and tissue damage
JP2016534035A (ja) 筋萎縮性側索硬化症を治療するための組成物及び方法
Kubo et al. Rho-ROCK inhibitors for the treatment of CNS injury
KR101239542B1 (ko) 탈수초화를 수반하는 병의 치료
JP5060293B2 (ja) 神経機能におけるｔａｊ
RS54160B1 (sr) Protein koji se vezuje za nogo receptor
Zhou et al. Targeting RPTPσ with lentiviral shRNA promotes neurites outgrowth of cortical neurons and improves functional recovery in a rat spinal cord contusion model
EA030716B1 (ru) Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
JP2024026109A (ja) 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤
JP2009517340A (ja) ドーパミン作動性ニューロンの神経突起成長および生存を促進するための方法
EP2904009B1 (en) Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein
US8399421B2 (en) Treatment for neuropathic pain due to spinal cord injury
JP5026083B2 (ja) 神経再生ペプチド及び脳損傷治療におけるそれらの使用方法
AU2005282217B2 (en) Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor
US20040009899A1 (en) Treating dominant disorders
EA043828B1 (ru) Антисмысловые олигонуклеотиды, нацеленные на альфа-синуклеин, и их применение
KR20100132869A (ko) 치료적 이용 방법
MX2008009620A (es) Antagonistas de receptores de nogo
AU2015337859A1 (en) Use of therapeutic agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111115

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120629

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120713

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120820

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120918

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150928

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees